Fair Warning: A Major Shift in Third-Party Testing Is Coming

I want to get ahead of this before it catches anyone off guard.

Over the next couple of months, you’re going to see a massive movement of peptide companies switching to new third-party testing labs. This isn’t one or two vendors quietly making a change — this is shaping up to be an industry-wide shift, and I’m already seeing it play out behind the scenes.

Why? The labs that have been the standard for a while now — Chromate, Vanguard, Freedom, MZ Biolabs — are falling short in ways that companies just can’t work around anymore:

• Freedom can’t perform sterility or heavy metals testing. That’s a huge gap in a full testing panel.

• Vanguard and Chromate are stuck in turnaround time hell. Companies are waiting way too long to get results back, and that bottleneck affects everything — inventory, launches, restocks, you name it.

When you can’t get the full panel of testing AND you can’t get results back in a reasonable timeframe, companies are going to look elsewhere. It’s just not sustainable.

What this means for you:

You’re going to start seeing COAs from labs you don’t recognize. New names, new formats, maybe new terminology. That’s okay — don’t panic. A new lab doesn’t automatically mean bad testing. It also doesn’t automatically mean good testing. The key is knowing how to evaluate them.

What I’m going to do:

I’ll do my best to keep you guys in the loop as these changes roll out. That means:

• Breaking down how to read COAs from these newer labs

• Doing background research into whether these labs are reputable

• Calling out anything that looks sketchy

This is one of those moments where the space is evolving in real time. Stay informed, ask questions, and as always — I’ve got your back.